Ann Arbor, Michigan 48109


Purpose:

This trial will determine the safety and tolerability of Pacritinib in patients with relapsed/refractory lymphoproliferative disorders.


Criteria:

Inclusion Criteria: - Diagnosis of any of the following: Relapsed/refractory cutaneous (stage IIb-IV) or peripheral T-cell lymphoma with progression after at least one prior therapy (including brentuximab vedotin for patients with anaplastic large cell lymphomas); Chronic lymphocytic leukemia (CLL), splenic marginal zone lymphoma (SMZL), Waldenstrom's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) or mantle cell lymphoma (MCL) with disease progression on ibrutinib or who discontinue ibrutinib due to toxicity/intolerance; any lymphoproliferative disorder who have failed at least 2 prior therapies and have had mutational analysis or sequencing studies performed in a CLIA certified laboratory demonstrating a mutation or gene fusion involving MyD88, JAK2, JAK3, TYK2, or IRAK1 that are known or suspected to be "activating" (gain-of-function). - Age ≥ 18 at time of enrollment - ECOG ≤ 2 (Eastern Cooperative Oncology Group scoring system used to quantify general well-being and activities of daily life; scores range from 0 to 5 where 0 represents perfect health and 5 represents death.) - Adequate organ and marrow function as defined in the protocol - Ability to take oral medication without crushing, dissolving or chewing tablets. - In the investigator's opinion, the patient requires immediate treatment. - Ability to understand and the willingness to sign a written informed consent. - In the investigator's opinion, the patient has the ability to communicate satisfactorily with the investigator and the study team, to participate fully in the study, and comply with all requirements. Exclusion Criteria: - History of, or a concurrent, clinically significant illness, medical condition or laboratory abnormality that, in the investigator's opinion, could affect the conduct of the study - Pregnant or breast feeding women - Unwilling or unable to use a medically acceptable form of contraception during the time of participation in the trial (sexual abstinence is permissible) unless documented successful vasectomy, hysterectomy, bilateral oophorectomy or post-menopausal for at least 2 years - Uncontrolled current illness, including, but not limited to the following: Ongoing or active infections requiring intravenous antimicrobials; symptomatic congestive heart failure defined as NYHA class II, III or IV (Appendix II); unstable angina pectoris within 6 months of study enrollment; unstable cardiac arrhythmia; history of myocardial infarction, stroke or intracranial hemorrhage within 6 months prior to enrollment; moderate to severe hepatic impairment (Child-Pugh class B or C); psychiatric illness or social situations that would limit compliance with study requirements - Known HIV infection - Known positive Hepatitis B surface antigen or Hep C virus - Recent (within 21 days of initiation of therapy, day 1) major surgery - Less than 14 days have elapsed since last radiation therapy or chemotherapy treatment or patient has not recovered from all clinically significant treatment-related toxicity; less than 90 days have passed since date of autologous stem cell transplant and patient has not recovered to ≤grade 1 toxicity related to this procedure - Use of systemic steroids (oral, inhaled, nasal, topical) at a dose less > 10 mg/day of prednisone - Prior treatment with pacritinib - Uncontrolled autoimmune hemolytic anemia (AIHA) or autoimmune thrombocytopenia (ITP). Coombs positivity in absence of hemolysis is not an exclusion. - Requires anticoagulation with heparin, warfarin or equivalent Vit K antagonist - History of significant bleeding (≥Grade 2 by CTCAE) history or complications (including bleeding that may have occurred while on ibrutinib) - Hypersensitivity or allergic reaction to compounds related to pacritinib - Treatment with potent CYP450 inducers and strong CYP3A4 inhibitors for which no alternative is available; treatment with strong CYP450 inducers or strong CYP3A4 inhibitors within 2 weeks of initiation of therapy, day 1 - Concurrent administration of QTc prolonging agents; significant QTc prolonging agents must be stopped within 5 half-lives of day 1. - Any gastrointestinal or metabolic condition that could interfere with the absorption of oral medication


NCT ID:

NCT03601819


Primary Contact:

Principal Investigator
Ryan Wilcox, MD, PhD
University of Michigan Rogel Cancer Center

Ryan Wilcox, MD, PhD
Phone: 734-615-9799
Email: rywilcox@med.umich.edu


Backup Contact:

N/A


Location Contact:

Ann Arbor, Michigan 48109
United States

Ryan Wilcox, MD, PhD
Phone: 734-615-9799
Email: rywilcox@umich.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.